Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L -DOPA-Induced Dyskinesias

Scott J Sherman, Miguel Estevez, Ari B. Magill, Torsten Falk

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to reduce L-DOPA-induced dyskinesia (LID), improve on time, and reduce depression. Based on the literature we hypothesize that low-dose ketamine may act as a 'chemical deep brain stimulation', by desynchronizing hypersynchronous oscillatory brain activity, including in the basal ganglia and the motor cortex. The presented PD case reports indicate tolerability, safety and long-term beneficial effects of low-dose ketamine infusion that should be further investigated in a properly controlled prospective clinical trial for treatment of LID, as well as the prevalent nonmotor features pain and depression in PD patients.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalCase Reports in Neurology
Volume8
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Dyskinesias
Ketamine
Intravenous Infusions
Parkinson Disease
Depression
Treatment-Resistant Depressive Disorder
Safety
Deep Brain Stimulation
Controlled Clinical Trials
Motor Cortex
Therapeutics
Basal Ganglia
Chronic Pain
Pain
Brain
Pharmaceutical Preparations

Keywords

  • Depression
  • Hypersynchrony
  • Levodopa
  • NMDA receptors
  • Pain
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L -DOPA-Induced Dyskinesias. / Sherman, Scott J; Estevez, Miguel; Magill, Ari B.; Falk, Torsten.

In: Case Reports in Neurology, Vol. 8, No. 1, 2016, p. 53-58.

Research output: Contribution to journalArticle

@article{c511249e8a0241ba892dbd0077aaf867,
title = "Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L -DOPA-Induced Dyskinesias",
abstract = "Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to reduce L-DOPA-induced dyskinesia (LID), improve on time, and reduce depression. Based on the literature we hypothesize that low-dose ketamine may act as a 'chemical deep brain stimulation', by desynchronizing hypersynchronous oscillatory brain activity, including in the basal ganglia and the motor cortex. The presented PD case reports indicate tolerability, safety and long-term beneficial effects of low-dose ketamine infusion that should be further investigated in a properly controlled prospective clinical trial for treatment of LID, as well as the prevalent nonmotor features pain and depression in PD patients.",
keywords = "Depression, Hypersynchrony, Levodopa, NMDA receptors, Pain, Parkinson's disease",
author = "Sherman, {Scott J} and Miguel Estevez and Magill, {Ari B.} and Torsten Falk",
year = "2016",
doi = "10.1159/000444278",
language = "English (US)",
volume = "8",
pages = "53--58",
journal = "Case Reports in Neurology",
issn = "1662-680X",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L -DOPA-Induced Dyskinesias

AU - Sherman, Scott J

AU - Estevez, Miguel

AU - Magill, Ari B.

AU - Falk, Torsten

PY - 2016

Y1 - 2016

N2 - Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to reduce L-DOPA-induced dyskinesia (LID), improve on time, and reduce depression. Based on the literature we hypothesize that low-dose ketamine may act as a 'chemical deep brain stimulation', by desynchronizing hypersynchronous oscillatory brain activity, including in the basal ganglia and the motor cortex. The presented PD case reports indicate tolerability, safety and long-term beneficial effects of low-dose ketamine infusion that should be further investigated in a properly controlled prospective clinical trial for treatment of LID, as well as the prevalent nonmotor features pain and depression in PD patients.

AB - Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to reduce L-DOPA-induced dyskinesia (LID), improve on time, and reduce depression. Based on the literature we hypothesize that low-dose ketamine may act as a 'chemical deep brain stimulation', by desynchronizing hypersynchronous oscillatory brain activity, including in the basal ganglia and the motor cortex. The presented PD case reports indicate tolerability, safety and long-term beneficial effects of low-dose ketamine infusion that should be further investigated in a properly controlled prospective clinical trial for treatment of LID, as well as the prevalent nonmotor features pain and depression in PD patients.

KW - Depression

KW - Hypersynchrony

KW - Levodopa

KW - NMDA receptors

KW - Pain

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84973531812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973531812&partnerID=8YFLogxK

U2 - 10.1159/000444278

DO - 10.1159/000444278

M3 - Article

VL - 8

SP - 53

EP - 58

JO - Case Reports in Neurology

JF - Case Reports in Neurology

SN - 1662-680X

IS - 1

ER -